Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis

Loading...
Thumbnail Image

Date

Journal Title

Journal ISSN

Volume Title

Publisher

King Faisal Specialist Hospital and Research Centre

Abstract

Despite availability of new and more effective therapies for chronic lymphocytic leukemia, presently this disease remains incurable unless eligible patients are offered an allogeneic hematopoietic cell transplant. Recent published clinical practice recommendations on behalf of the American Society for Blood and Marrow Transplantation relegated the role of for allogeneic hematopoietic cell transplantation to later stages of the disease. To our knowledge, no randomized controlled trial has been performed to date comparing myeloablative versus reduced intensity conditioning regimens in chronic lymphocytic leukemia patients eligible for the procedure. We performed a systematic review/meta-analysis to assess the efficacy of allogeneic hematopoietic cell transplantation when using myeloablative or reduced intensity conditioning regimens. We report the results in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Based on lower non-relapse mortality and slightly better overall survival rates, reduced intensity conditioning regimens appear to be the most desirable choice whenever the procedure is indicated for this disease. It appears highly unlikely that a RCT will be ever performed comparing reduced intensity vs. myeloablative allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia. In the absence of such a study, results of this systematic review/meta-analysis represent the best available evidence supporting this recommendation whenever indicated in patients with chronic lymphocytic leukemia. © 2017 King Faisal Specialist Hospital & Research Centre

Description

Keywords

Allogeneic hematopoietic cell transplantation, Chronic lymphocytic leukemia, Overall survival, Reduced intensity conditioning, Allografts, Hematopoietic stem cell transplantation, Humans, Leukemia, lymphocytic, chronic, b-cell, Transplantation conditioning, Alemtuzumab, Busulfan, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Fludarabine, Melphalan, Rituximab, Thymocyte antibody, Allogeneic hematopoietic stem cell transplantation, Cancer survival, Chronic lymphatic leukemia, Clinical effectiveness, Clinical practice, Disease course, Human, Intermethod comparison, Leukemia relapse, Medical society, Meta analysis, Mortality, Myeloablative conditioning, Practice guideline, Randomized controlled trial (topic), Review, Systematic review, Treatment indication, United states, Allograft, Procedures

Citation

Endorsement

Review

Supplemented By

Referenced By